Literature DB >> 10488798

Symposium on antimicrobial agents--Part XII. Vancomycin.

M P Wilhelm1, L Estes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10488798     DOI： 10.4065/74.9.928

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  18 in total

Review 1.  Approaching and analyzing a large literature on vancomycin monitoring and pharmacokinetics.

Authors:  Patricia Lee; David DiPersio; Rebecca N Jerome; Arthur P Wheeler
Journal:  J Med Libr Assoc       Date:  2007-10

2.  [Prevention of transmission of methicillin-resistant Staphylococcus aureus (MRSA) infection: standard precautions instead of isolation: a 6-year surveillance in a university hospital].

Authors:  I Kappstein; K van der Mühlen; D Meschzan; V Vatou; S Bieg-Habermann
Journal:  Chirurg       Date:  2009-01       Impact factor: 0.955

3.  Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital.

Authors:  Aylin Acar Sancar; Selen Yegenoglu; Robin de Vries; Maarten J Postma; Nimet Simsek; Petros Pechlivanoglou; Serhat Unal
Journal:  Pharm World Sci       Date:  2008-09-21

4.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Comparative in vitro efficacies of various catheter lock solutions.

Authors:  Robert J Sherertz; Michael S Boger; Casey A Collins; Lori Mason; Issam I Raad
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

6.  The intestinal microbiota are necessary for stressor-induced enhancement of splenic macrophage microbicidal activity.

Authors:  Rebecca G Allen; William P Lafuse; Jeffrey D Galley; Mohamed M Ali; Brian M M Ahmer; Michael T Bailey
Journal:  Brain Behav Immun       Date:  2011-11-12       Impact factor: 7.217

7.  Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.

Authors:  John Weigelt; Kamal Itani; Dennis Stevens; William Lau; Matthew Dryden; Charles Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 8.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

9.  Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.

Authors:  Megan E DelDot; Jeffrey Lipman; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

10.  Vancomycin and home health care.

Authors:  Thomas G Fraser; Valentina Stosor; Qiong Wang; Anne Allen; Teresa R Zembower
Journal:  Emerg Infect Dis       Date:  2005-10       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.